immunotherapy – Medxy AI

Neoadjuvant Immunotherapy in dMMR Colon Cancer: A Breakthrough in Survival Outcomes

By MedXY 11/09/2026

The NICHE-2 trial demonstrates that neoadjuvant immunotherapy with ipilimumab and nivolumab yields 100% three-year disease-free and five-year overall survival in mismatch repair-deficient colon cancer patients, marking a potential new standard of care.

Clinical Updates Hematology-Oncology

Harnessing CD4+ T Cells: A New Frontier in Targeted Immunotherapy for ALK-Positive T-Cell Lymphoma

By MedXY 11/08/2026

This article delineates the pivotal role of CD4+ T cells in mediating immune responses against ALK-positive anaplastic large cell lymphoma, highlighting preclinical evidence supporting immune checkpoint inhibitors as a promising therapeutic strategy.

Clinical Updates Oncology Respiratory

Decoding the Immune Landscape in NSCLC: Oncogene-Specific Spatial Proteomics Identifies Prognostic Niches and Therapeutic Targets

By MedXY 11/08/2026

Spatial proteomics reveals how EGFR and KRAS mutations distinctly remodel the immune microenvironment in non-small cell lung cancer, identifying immune niches and prognostic markers that may guide immunotherapy strategies.

放化疗后不可切除Ⅲ期非小细胞肺癌巩固治疗：benmelstobart 联用或不联用 anlotinib 的 R-ALPS 试验解读

Clinical Updates Oncology Respiratory

Evaluating Benmelstobart With or Without Anlotinib as Consolidation Therapy After Chemoradiotherapy in Unresectable Stage III NSCLC: Insights from the R-ALPS Trial

By MedXY 11/06/2026

The R-ALPS randomized trial confirms that benmelstobart improves progression-free survival in unresectable stage III NSCLC patients post-chemoradiotherapy, while adding anlotinib does not significantly enhance efficacy and raises severe toxicity risks.

Allergy & Immunology Clinical Updates Nephrology

Dual Remission of Atopic Dermatitis and Frequently Relapsing Nephrotic Syndrome With Dupilumab

By MedXY 11/04/2026

A 9-year-old girl with atopic dermatitis and relapsing nephrotic syndrome achieved sustained remission of both conditions after dupilumab therapy, enabling withdrawal of steroids and tacrolimus.

Allergy & Immunology Clinical Updates Hematology-Oncology

Navigating Autoimmune Neutropenia in Adults: Diagnosis and Tailored Treatment Strategies

By MedXY 11/04/2026

Autoimmune neutropenia (AiN) in adults, though rare, is a chronic condition predominantly affecting women with autoimmune comorbidities. Treatment prioritizes observation, with therapies aimed at boosting neutrophil counts or modulating immune responses when necessary.

進展型小細胞肺癌の維持療法におけるタルラタマブ＋デュルバルマブ：生存転帰を大きく改善する新展開

Clinical Updates Oncology Respiratory

Tarlatamab Plus Durvalumab as Maintenance Therapy in Extensive-Stage Small-Cell Lung Cancer: A Breakthrough in Survival Outcomes

By MedXY 11/04/2026

This phase 3 trial shows that tarlatamab combined with durvalumab significantly improves overall and progression-free survival compared to durvalumab alone as maintenance therapy post-first-line chemoimmunotherapy in extensive-stage small-cell lung cancer.

Allergy & Immunology Clinical Updates Rheumatology

Isotype-Specific Autoantibody Remodeling in Antiphospholipid Syndrome via BAFF-APRIL Blockade

By MedXY 11/01/2026

This study reveals that dual BAFF-APRIL blockade with telitacicept distinctly remodels pathogenic autoantibodies in antiphospholipid syndrome, showing differential effects across immunoglobulin isotypes and identifying marrow plasma-cell clonotypes linked to persistent IgG autoantibodies.

PD-L1阴性晚期非鳞状NSCLC一线治疗迎来新突破：sacituzumab tirumotecan联合pembrolizumab

Clinical Updates Oncology

Sacituzumab Tirumotecan Plus Pembrolizumab in PD-L1-Negative Advanced Non-Squamous NSCLC: A Paradigm Shift in First-Line Therapy

By MedXY 11/01/2026

Sacituzumab tirumotecan combined with pembrolizumab significantly improves progression-free survival in PD-L1-negative advanced nonsquamous NSCLC compared to chemotherapy plus pembrolizumab, offering a promising new treatment standard with manageable safety profile.

news OB/GYN & Women's Health Oncology

Disparities in Immunotherapy Use for Advanced Endometrial Cancer Among Older Adults: Insights from NCDB Analysis

By MedXY 10/27/2026

Immunotherapy use in older patients with advanced endometrial cancer has increased over recent years but remains lower among the oldest and racial minorities, highlighting persisting treatment disparities.

Hematology-Oncology news Oncology

Mapping the Tumor Microenvironment in Multiple Myeloma: Insights from Single-Cell Analysis Across Disease Stages

By MedXY 10/16/2026

This study provides a comprehensive single-cell immune atlas of multiple myeloma, revealing dynamic tumor microenvironment ecotypes linked to disease progression, immune dysfunction, and treatment response, offering new avenues for precision immunotherapy.

Clinical Updates news Oncology

Disitamab Vedotin Plus Tislelizumab in Transurethrally Unresectable, ERBB2-Positive, Non-Muscle-Invasive Bladder Cancer: An Emerging Therapeutic Strategy

By MedXY 10/15/2026

This review synthesizes evidence on disitamab vedotin combined with tislelizumab showing promising efficacy and safety in treating transurethrally unresectable ERBB2-positive very high-risk NMIBC, filling a crucial therapeutic gap for patients ineligible for cystectomy.

Hematology-Oncology news Oncology

High Efficacy and Safety of Glofitamab Plus Polatuzumab-R-CHP in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Multicenter Study

By MedXY 10/11/2026

A phase II trial shows that adding the bispecific antibody glofitamab to polatuzumab-R-CHP achieves a 95% complete response rate and durable remission with minimal cytokine release syndrome in high-risk diffuse large B-cell lymphoma.

Hematology-Oncology news Oncology

Targeting the FGF18-FGFR3 Axis: A New Frontier in Acute Myeloid Leukemia Therapy

By MedXY 10/09/2026

FGF18 produced by stromal fibroblasts promotes AML progression via FGFR3-mediated AKT-mTOR signaling, forming a feed-forward loop that impairs CD8+ T-cell immunity. Neutralizing FGF18 synergizes with PD-1 blockade, suggesting a novel therapeutic strategy for AML.

Diabetes & Endocrinology news Oncology

Immunotherapy-Induced Endocrine Dysfunction in Gynecologic Oncology: Clinical Insights from a Retrospective Cohort Study

By MedXY 10/04/2026

This study highlights the prevalence, clinical features, and management challenges of immune-related thyroid and diabetes toxicities in gynecologic cancer patients treated with immunotherapy, emphasizing the need for proactive endocrine monitoring and long-term care.

Clinical Updates Diabetes & Endocrinology news Pediatrics

Precision Medicine in Type 1 Diabetes Prevention: Long-Term Delayed Onset of Stage 3 Diabetes After GAD-Alum Treatment in HLA-DR3-DQ2-Positive Children

By MedXY 10/04/2026

GAD-alum immunotherapy significantly delays progression to stage 3 type 1 diabetes in children positive for the HLA-DR3-DQ2 haplotype, underscoring precision medicine's role in managing autoimmunity.

Hematology-Oncology news

Harnessing Antigen-Specific Donor Regulatory T Cells to Prevent GVHD in Allogeneic Hematopoietic Cell Transplantation

By MedXY 09/30/2026

This phase 1 trial demonstrates that expanded minor histocompatibility antigen-specific donor regulatory T cells, combined with sirolimus prophylaxis, are safe and show promise in preventing acute and chronic GVHD post-allogeneic HCT with durable in vivo persistence.

Hematology-Oncology news Oncology

Precision Immunotherapy in Acute Myeloid Leukemia: Advancing Beyond Traditional Targets

By MedXY 09/28/2026

Recent advances in identifying leukemia-restricted antigens enable subtype-specific immunotherapies in AML that selectively target malignant cells while sparing normal hematopoiesis, offering a promising new paradigm for precision treatment.

news Oncology

Decoding Cellular Interactions to Enhance Neoadjuvant PD-L1 Blockade Response in Esophageal Squamous Cell Carcinoma

By MedXY 09/22/2026

This study reveals coordinated cellular programs underlying response and resistance to neoadjuvant PD-L1 blockade in ESCC, highlighting potential combinatorial immunotherapy targets for personalized treatment strategies.

Clinical Updates news Rheumatology

Dapirolizumab Pegol Improves Disease Activity in Systemic Lupus Erythematosus: Evidence from Phase 3 PHOENYCS GO Trial and Prior Studies

By MedXY 09/22/2026

Dapirolizumab pegol, a CD40 ligand inhibitor, significantly improves disease activity in moderate-to-severe SLE over 48 weeks when added to standard care, supported by robust phase 3 trial data and pharmacokinetic findings.